Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Saved in:

Bibliographic Details
Published in:	Blood Cancer J
Main Authors:	Derman, Benjamin A., Stefka, Andrew T., Jiang, Ken, McIver, Amanda, Kubicki, Tadeusz, Jasielec, Jagoda K., Jakubowiak, Andrzej J.
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group UK 2021
Subjects:	Correspondence
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7873068/ https://ncbi.nlm.nih.gov/pubmed/33563912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00418-2
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items